Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Monday that it has launched its Fluphenazine Hydrochloride Tablets, USP in 1mg, 2.5mg, 5mg, and 10mg strengths.
According to IQVIA, the product market had US sales of around USD30m for the 12 months ending January 2023.
The product is a generic version of the brand product, Prolixin. Prolixin is a registered trademark of E.R. Squibb & Sons, Inc.
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical